HIV-1 Variable Loop 2 and its Importance in HIV-1 Infection and Vaccine Development

被引:27
|
作者
Rao, Mangala [1 ]
Peachman, Kristina K. [1 ,3 ]
Kim, Jiae [1 ,3 ]
Gao, Guofen [2 ]
Alving, Carl R. [1 ]
Michael, Nelson L. [1 ]
Rao, Venigalla B. [2 ]
机构
[1] Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD 20910 USA
[2] Catholic Univ Amer, Washington, DC 20064 USA
[3] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA
关键词
alpha 4 beta 7 integrin receptor; HIV-1; gp120; RV144; V2; loop; vaccine; HUMAN-IMMUNODEFICIENCY-VIRUS; NEUTRALIZING ANTIBODY-RESPONSE; GP120 ENVELOPE GLYCOPROTEIN; T-CELL DEPLETION; SIMIAN IMMUNODEFICIENCY; MONOCLONAL-ANTIBODIES; EFFICACY TRIAL; V1/V2; REGION; DOUBLE-BLIND; INTEGRIN ALPHA(4)BETA(7);
D O I
10.2174/1570162X113116660064
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A vaccine that can prevent the transmission of HIV-1 at the site of exposure to the host is one of the best hopes to control the HIV-1 pandemic. The trimeric envelope spike consisting of heterodimers, gp120 and gp41, is essential for virus entry and thus has been a key target for HIV-1 vaccine development. However, it has been extremely difficult to identify the types of antibodies required to block the transmission of various HIV-1 strains and the immunogens that can elicit such antibodies due to the high genetic diversity of the HIV-1 envelope. The modest efficacy of the gp120 HIV-1 vaccine used in the RV144 Thai trial, including the studies on the immune correlates of protection, and the discovery of vaccine-induced immune responses to certain signature regions of the envelope have shown that the gp120 variable loop 2 (V2) is an important region. Since there is evidence that the V2 region interacts with the integrin 4 7 receptor of the host cell, and that this interaction might be important for virus capture, induction of antibodies against V2 loop could be postulated as one of the mechanisms to prevent the acquisition of HIV-1. Immunogens that can induce these antibodies should therefore be taken into consideration when designing HIV-1 vaccine formulations.
引用
收藏
页码:427 / 438
页数:12
相关论文
共 50 条
  • [22] Antibodies in HIV-1 Vaccine Development and Therapy
    Klein, Florian
    Mouquet, Hugo
    Dosenovic, Pia
    Scheid, Johannes F.
    Scharf, Louise
    Nussenzweig, Michel C.
    SCIENCE, 2013, 341 (6151) : 1199 - 1204
  • [23] HIV-1 Vaccine Development After STEP
    Barouch, Dan H.
    Korber, Bette
    ANNUAL REVIEW OF MEDICINE, 2010, 61 : 153 - 167
  • [24] Potential of recombinant Mycobacterium paragordonae expressing HIV-1 Gag as a prime vaccine for HIV-1 infection
    Byoung-Jun Kim
    Bo-Ram Kim
    Yoon-Hoh Kook
    Bum-Joon Kim
    Scientific Reports, 9
  • [25] B cell immunopathology during HIV-1 infection: Lessons to learn for HIV-1 vaccine design
    Cagigi, Alberto
    Nilsson, Anna
    De Milito, Angelo
    Chiodi, Francesca
    VACCINE, 2008, 26 (24) : 3016 - 3025
  • [26] Progress in the development of a preventive HIV-1 vaccine
    Elizaga, ML
    McElrath, MJ
    CLINICS IN LABORATORY MEDICINE, 2002, 22 (04) : 963 - +
  • [27] Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?
    Leonidas Stamatatos
    Lynn Morris
    Dennis R Burton
    John R Mascola
    Nature Medicine, 2009, 15 : 866 - 870
  • [28] Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?
    Stamatatos, Leonidas
    Morris, Lynn
    Burton, Dennis R.
    Mascola, John R.
    NATURE MEDICINE, 2009, 15 (08) : 866 - 870
  • [29] Potential of recombinant Mycobacterium paragordonae expressing HIV-1 Gag as a prime vaccine for HIV-1 infection
    Kim, Byoung-Jun
    Kim, Bo-Ram
    Kook, Yoon-Hoh
    Kim, Bum-Joon
    SCIENTIFIC REPORTS, 2019, 9 (1)